deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02578641

A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients (VANCE)

A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma(NPC) Patients

Sponsor: Tessa Therapeutics

Conditions Nasopharyngeal Carcinoma
Interventions autologous EBV specific Cytotoxic T cells combination IV gemcitabine and IV carboplatin (AUC2)
Updated 19 times since 2017 Last updated: Jun 7, 2023 Started: Jul 31, 2014 Primary completion: Feb 28, 2022 Completion: Feb 28, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Nasopharyngeal Carcinoma and is currently completed. Tessa Therapeutics leads this study, which shows 19 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshot~Aug 2017 – ~Dec 2017 · 4 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Apr 2019 · 10 months · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jul 2019 · 2 months · monthly snapshot~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Jan 2020 · 4 months · monthly snapshot~Jan 2020 – ~Apr 2020 · 3 months · monthly snapshot~Apr 2020 – ~Aug 2020 · 4 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Nov 2022 · 19 months · monthly snapshot~Nov 2022 – ~Jul 2023 · 8 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jul 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Nov 2022 — Jul 2023 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

▶ Show 14 earlier versions

  1. Apr 2021 — Nov 2022 [monthly]

    Active Not Recruiting PHASE3

  2. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE3

  3. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  4. Apr 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE3

  5. Jan 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  6. Sep 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

  7. Jul 2019 — Sep 2019 [monthly]

    Recruiting PHASE3

  8. May 2019 — Jul 2019 [monthly]

    Recruiting PHASE3

  9. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE3

  10. Jun 2018 — Apr 2019 [monthly]

    Recruiting PHASE3

  11. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE3

  12. Aug 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  13. Feb 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  14. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Jul 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Tessa Therapeutics
Data source: Tessa Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bangkok, Thailand , Boston, United States , Changhua, Taiwan , Chiang Mai, Thailand , Dallas, United States , Duarte, United States , George Town, Malaysia , Houston, United States , Johor Bahru, Malaysia , Kaohsiung City, Taiwan and 12 more locations